Showing 5 posts of 5 posts found.

NICE authorises Takeda’s Alunbrig for ALK-positive advanced non-small cell lung cancer

December 10, 2020
Sales and Marketing ALK-positive advanced non-small cell lung cancer, Alunbrig, NICE, Takeda

NICE has published its final appraisal of Takeda’s Alunbrig (brigatinib), recommending the therapy for the treatment of ALK-positive advanced non-small …


Takeda’s Alunbrig outclasses Xalkori to secure EU approval in ALK+ advanced non-small cell lung cancer

April 7, 2020
Manufacturing and Production, Sales and Marketing Alunbrig, Europe, Takeda, pharma

The European Commission has ruled to expand the current approved indication of Takeda’s Alunbrig (brigatinib), authorising the drug as a …


European approval for Takeda’s Alunbrig in ALK+ advanced non-small cell lung cancer

November 27, 2018
Research and Development, Sales and Marketing Alunbrig, Cancer, Takeda, lung cancer, pharma

Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive …


Takeda’s lung cancer treatment Alunbrig proves successful in Phase III trial

September 26, 2018
Research and Development Alunbrig, R&D, Takeda, phase III, research

Japanese pharma firm Takeda have announced that lung cancer treatment Alunbrig has proven successful in reducing the risk of disease …


Takeda’s Alunbrig topples Pfizer’s Xalkori in ALK-positive lung cancer

July 27, 2018
Medical Communications, Research and Development Alunbrig, Cancer, NSCLC, Pfizer, Takeda, Xalkori, lung cancer, pharma

Takeda has unveiled new Phase 3 data showing that its tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) not only met its …

Latest content